Interview: Pfizer's Smith On Building A Gene Therapy Business
Pfizer entered the gene therapy space in 2014 and now has three programs in the clinic. Robert Smith, head of Pfizer’s gene therapy unit, spoke to Scrip about the company strategy, as well as the regulatory and reimbursement landscape.
You may also be interested in...
Pfizer announced its entry into the gene therapy space in December 2014, when it signed a deal with Spark Therapeutics for hemophilia B. Scrip takes a look at progress to date.
Pfizer will be active in business development, management said, but with a focus on building out the pipeline with bolt-on deals in the range of a "few billion." Gene therapy remains one area of interest.
The big pharma has acquired a 15% equity stake in the privately-held gene therapy developer and an option to purchase all outstanding shares.